Detailed Information

Cited 19 time in webofscience Cited 17 time in scopus
Metadata Downloads

Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3)

Authors
Go, Se-IlLee, Sang-CheolBae, Woo KyunZang, Dae YoungLee, Hyun WooJang, Joung SoonJi, Jun HoKim, Jung HoonPark, SanggonSym, Sun JinYang, YaewonJeon, So YeonHwang, In GyuOh, Sung YongKang, Jung Hun
Issue Date
Nov-2021
Publisher
Pergamon Press Ltd.
Keywords
Pancreatic neoplasms; Modified FOLFIRINOX; S-1; Second-line chemotherapy; Gemcitabine; Randomised controlled trial
Citation
European Journal of Cancer, v.157, pp 21 - 30
Pages
10
Indexed
SCIE
SCOPUS
Journal Title
European Journal of Cancer
Volume
157
Start Page
21
End Page
30
URI
https://scholarworks.gnu.ac.kr/handle/sw.gnu/3076
DOI
10.1016/j.ejca.2021.08.002
ISSN
0959-8049
1879-0852
Abstract
Background: The efficacy of modified FOLFIRINOX (mFOLFIRINOX) as a second-line chemotherapy treatment for metastatic pancreatic adenocarcinoma (mPAC), remains unclear. This multi-center randomised phase III trial aimed to elucidate the efficacy of mFOLFIRINOX as a second-line chemotherapy treatment for mPAC patients with good performance status. Patients and methods: Eighty mPAC patients (age, 19-75 years) refractory to first-line gemcitabine-based chemotherapy were randomly selected to receive mFOLFIRINOX or S-1. mFOLFIRINOX comprised oxaliplatin (65 mg/m(2)), irinotecan (135 mg/m(2)), and leucovorin (400 mg/m(2)) on day 1 and continuous 5-FU infusion (1000 mg/m(2)) over 24 h on days 1-2 every 2 weeks. S-1 comprised body surface area-dependent oral S-1, divided into two doses per day on days 1-28 every 6 weeks. Results: Overall survival was the primary endpoint. The objective response and disease control rates were higher in the mFOLFIRINOX than in the S-1 group (15% versus 2%; p = .04 and 67% versus 37%; p = .007). The median progression-free survival rates were 5.2 and 2.2 months in the mFOLFIRINOX and S-1 groups, respectively (adjusted hazard ratio [HR]: .4; 95% confidence interval [CI]: .2-.6; p < .001). The median overall survival rates were 9.2 and 4.9 months in the mFOLFIRINOX and S-1 groups, respectively (adjusted HR: .4; 95% CI: .2-.7; p = .002). Grade 3-4 adverse events occurred in 56% and 17% of the patients in the mFOLFIRINOX and S-1 groups, respectively (p < .001). Conclusion: Administration of mFOLFIRINOX as a second-line chemotherapy treatment for mPAC patients refractory to gemcitabine-based chemotherapy resulted in increased survival rates than S-1 treatment alone. (C) 2021 Elsevier Ltd. All rights reserved.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medicine > Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kang, Jung Hun photo

Kang, Jung Hun
의과대학 (의학과)
Read more

Altmetrics

Total Views & Downloads

BROWSE